Transcend Therapeutics 

Transcend Therapeutics 

  • Founded: 2021
  • Location: New York, NY
  • Employee range: 1 - 10
  • Therapy area: mental illness
  • Drug types: PSY
  • Lead product: TSND-201
  • Funding: $40M A Feb 2023
  • Investors: Alpha Wave Global, Integrated Investment Partners

job board

Short description:


Drug notes:

Contact us to add description:

Long description:

Transcend Therapeutics is discovering and developing psychedelic medicines for neuropsychiatry. The largest cause of disability worldwide is now neuropsychiatric illnesses with 1 billion people currently suffering; however there is little investment and innovation in developing new treatments. Transcend aims to rectify this problem by identifying psychedelics with clinical and nonclinical safety profiles and prioritizing those with therapeutic effect. Patient access enables Transcend to then verify treatments and identify those with shorter treatment durations, minimal patient inebriation and fewer undesirable effects compared to traditional psychedelics. Transcend’s lead product has demonstrated >85% response rates in patients with depression and PTSD.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy